Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules

European Journal of Immunology

Volumn 31, Issue 6, 2001, Pages 1837-1846

  Texier, Catherine ^a   Pouvelle Moratille, Sandra ^a   Busson, Marc ^a   Charron, Dominique ^a   Ménez, André ^a   Maillère, Bernard ^a,b  

^a CEA SACLAY   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Allergy; Bee venom; Binding assay; HLA DR; Peptide

Indexed keywords

ALLERGEN; AMINO ACID; ANTIGEN; BEE VENOM; HLA DR ANTIGEN; PEPTIDE;

ALLELE; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DOCUMENTATION; GENE LOCUS; GENETIC POLYMORPHISM; HAPLOTYPE; IMMUNOTHERAPY; MOLECULE; POPULATION; PRIORITY JOURNAL;

ALLELES; AMINO ACID SEQUENCE; BEE VENOMS; COMPUTER SIMULATION; HLA-DR ANTIGENS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHOLIPASES A; PROTEIN STRUCTURE, SECONDARY;

EID: 0034975142     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200106)31:6<1837::AID-IMMU1837>3.0.CO;2-H     Document Type: Article

References (40)

1. Structural analysis of peptides capable of binding to more than one la antigen
2. A novel first primary anchor extends the MHC class II I-Ad binding motif to encompass nine amino acids
3. MHC ligands and peptide motifs: First listing
4. Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires
5. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
6. Allele and haplotype frequencies for HLA loci in various ethic groups
7. Correlation of structure with T cell responses of the three members of the HLA-DRw52 allelic series
8. Determinants of T cell reactivity to the Mycobacterium leprae GroES homologue
9. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: Evidence of molecular mimicry in human autoimmune diseases
10. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: Overlapping natural and artificial determinants in the human acetylcholine receptor
11. T cell responses to allergens: Epitope-specificity and clinical relevance
12. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures
13. Role of interleukin 10 in specific immunotherapy
14. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in patients allergic to bee venom
15. Engineering of the major house dust mite allergen Der f 2 for allergen- specific immunotherapy
16. Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy
17. Treatment of cat allergy with T cell reactive peptides
18. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety
19. Mapping human T cell epitopes on phospholipase A2: The major bee-venom allergen
20. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2
21. Delineation of PLA2 epitopes using short or long overlapping synthetic peptides: Interest for specific immunotherapy
22. HLA-DR restricted peptide candidates for bee venom immunotherapy
23. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides
24. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain
25. DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DR beta 1 alleles
26. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands
27. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide
28. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3
29. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein
30. Analysis of anchor residues in a naturally processed HLA-DR53 ligand
31. Evolution of the human HLA-DR region
32. Cutting edge: A single, essential hydrogen bond controls the stability of peptide-MHC class II complexes
33. Deviant trafficking of I-Ad mutant molecules is reflected in their peptide binding properties
34. Alteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal
35. N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively
36. Polymorphism of human la antigens: Gene conversion between two DR beta loci results in a new HLA-D/DR specificity
37. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs
38. On the diversity and heterogeneity of H-2d restricted determinants and T cell epitopes from the major bee venom allergen
39. A system for X-ray crystallography and NMR